Nicholas C Turner Selected Research

palbociclib

1/2022	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
1/2021	Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
1/2021	Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
1/2021	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
1/2021	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
1/2021	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
11/2020	Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
10/2019	Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
2/2019	Palbociclib and Fulvestrant in Breast Cancer. Reply.
1/2019	Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicholas C Turner Research Topics

Disease

57	Breast Neoplasms (Breast Cancer) 10/2022 - 08/2006
48	Neoplasms (Cancer) 01/2022 - 02/2008
8	Neutropenia 01/2021 - 07/2015
5	Disease Progression 01/2022 - 07/2015
4	Infections 01/2021 - 01/2017
4	Triple Negative Breast Neoplasms 01/2021 - 12/2010
3	Febrile Neutropenia 01/2021 - 07/2015
3	Fatigue 10/2020 - 07/2015
2	Exanthema (Rash) 10/2020 - 10/2020
2	Ovarian Neoplasms (Ovarian Cancer) 11/2017 - 01/2016
2	Leukopenia 01/2017 - 07/2015
2	Lung Neoplasms (Lung Cancer) 01/2015 - 12/2010
1	Lobular Carcinoma 04/2022
1	Microsatellite Instability 01/2022
1	Circulating Neoplastic Cells 01/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021
1	Diarrhea 10/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	Genetic Translocation (Chromosomal Translocation) 01/2017
1	Cholangiocarcinoma 01/2017
1	Bone Diseases (Bone Disease) 04/2016
1	Neoplasm Metastasis (Metastasis) 04/2016
1	Melanoma (Melanoma, Malignant) 01/2016
1	Stomach Neoplasms (Stomach Cancer) 01/2016
1	Colorectal Neoplasms (Colorectal Cancer) 01/2016
1	Oncogene Addiction 01/2016
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016
1	Glioblastoma (Glioblastoma Multiforme) 01/2016
1	Residual Neoplasm 08/2015
1	Thrombocytopenia (Thrombopenia) 07/2015
1	Anemia 07/2015

Drug/Important Bio-Agent (IBA)

22	palbociclibIBA 01/2022 - 07/2015
19	Fulvestrant (Faslodex)FDA Link 01/2022 - 07/2015
19	Hormones (Hormone)IBA 01/2022 - 07/2015
14	Circulating Tumor DNAIBA 01/2022 - 08/2015
12	Estrogen ReceptorsIBA 01/2021 - 08/2011
8	ErbB Receptors (EGF Receptor)IBA 01/2022 - 07/2015
8	Phosphotransferases (Kinase)IBA 01/2017 - 08/2011
7	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2020 - 05/2008
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2013
6	Cyclin-Dependent Kinase 4IBA 01/2021 - 01/2017
5	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2020 - 02/2015
4	capivasertibIBA 10/2020 - 01/2020
4	PlatinumIBA 01/2019 - 11/2012
3	Cell-Free Nucleic AcidsIBA 01/2022 - 11/2017
3	Phenobarbital (Luminal)FDA Link 11/2020 - 12/2013
3	human ERBB2 proteinIBA 01/2020 - 10/2016
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 06/2012 - 12/2010
2	eribulin FDA Link 10/2022 - 10/2021
2	Vinorelbine (Navelbine)FDA LinkGeneric 10/2022 - 10/2021
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2022 - 10/2020
2	Aromatase InhibitorsIBA 10/2020 - 01/2016
2	exemestane (Aromasin)FDA Link 10/2020 - 01/2016
2	olaparibIBA 10/2020 - 01/2017
2	Paclitaxel (Taxol)FDA LinkGeneric 10/2020 - 01/2020
2	CyclinsIBA 10/2019 - 01/2016
2	LigandsIBA 06/2012 - 08/2011
2	Proteins (Proteins, Gene)FDA Link 12/2008 - 08/2006
1	TubulinIBA 10/2022
1	Tubulin ModulatorsIBA 10/2022
1	Cadherins (E-Cadherin)IBA 04/2022
1	Cell Adhesion MoleculesIBA 04/2022
1	pembrolizumabIBA 01/2022
1	N 30IBA 01/2022
1	AlpelisibIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	dostarlimabIBA 01/2022
1	niraparibIBA 10/2021
1	Capecitabine (Xeloda)FDA Link 10/2021
1	Gemcitabine FDA Link 10/2021
1	tetrachloroisophthalonitrile (Bravo)IBA 10/2021
1	Ado-Trastuzumab EmtansineIBA 10/2021
1	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2021
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 10/2020
1	neratinibIBA 10/2020
1	InterferonsIBA 01/2020
1	E-3810IBA 01/2020
1	rucaparibIBA 01/2020
1	talazoparibIBA 01/2019
1	Tyrosine Kinase InhibitorsIBA 01/2019
1	SaltsIBA 01/2017
1	adavosertibIBA 01/2017
1	Therapeutic UsesIBA 01/2017
1	Goserelin (Zoladex)FDA Link 01/2017
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2017
1	Pharmaceutical PreparationsIBA 10/2016
1	Cytostatic AgentsIBA 01/2016
1	AZD4547IBA 01/2016
1	Anastrozole (Arimidex)FDA LinkGeneric 01/2016
1	abemaciclibIBA 01/2016
1	DNA HelicasesIBA 04/2015

Therapy/Procedure

41	Therapeutics 01/2022 - 02/2008
14	Drug Therapy (Chemotherapy) 10/2022 - 12/2010
3	Adjuvant Chemotherapy 10/2021 - 10/2019
3	Neoadjuvant Therapy 10/2019 - 12/2010
2	Radiotherapy 01/2022 - 01/2020
1	Drug Tapering 10/2016
1	Intramuscular Injections 04/2016